Elektrofi
Paul Brown has a wealth of work experience, beginning in 2005 as an Assistant Language Teacher for the Yuza Board of Education - JET Programme. Paul then moved on to the University of Bristol in 2009 to pursue a Ph.D. From 2013 to 2016, Paul held the role of Postdoctoral Researcher and Safety Representative at the Massachusetts Institute of Technology (MIT). Finally, Paul has served as both Associate Director and Head of Drug Product Development and a Senior Research Scientist at Elektrofi since 2016.
Paul Brown completed a Doctor of Philosophy (Ph.D.) in Physical Chemistry from the University of Bristol between 2009 and 2012. Paul obtained a Master of Science (MSc) in Chemistry from the University of Bristol between 2000 and 2005. Paul also completed a Master of Science (MSc) in Chemistry from Heidelberg University between 2003 and 2004. Paul attended NBHS, as well as the University of Düsseldorf, but no further information is available about these experiences.
Elektrofi
1 followers
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.